Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies

The nuclear export receptor, Exportin 1 (XPO1), mediates transport of growth-regulatory proteins including tumor suppressors and is overactive in many cancers, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and aggressive lymphomas. Oral Selective Inhibitor of Nuclear Ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Hing, Zachary A., Fung, Ho Yee Joyce, Ranganathan, Parvathi, Mitchell, Shaneice, El-Gamal, Dalia, Woyach, Jennifer A., Williams, Katie, Goettl, Virginia M., Smith, Jordan, Yu, Xueyan, Meng, Xiaomei, Sun, Qingxiang, Cagatay, Tolga, Lehman, Amy M., Lucas, David M., Baloglu, Erkan, Shacham, Sharon, Kauffman, Michael G., Byrd, John C., Chook, Yuh Min, Garzon, Ramiro, Lapalombella, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143172/
https://www.ncbi.nlm.nih.gov/pubmed/27323910
http://dx.doi.org/10.1038/leu.2016.136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143172/
https://www.ncbi.nlm.nih.gov/pubmed/27323910
http://dx.doi.org/10.1038/leu.2016.136

Ejemplares similares